Hamps Bio Ltd

Financials

• Standalone revenue from operations: ₹851.65 lakhs.
• Consolidated revenue from operations: ₹847.46 lakhs.
• Standalone net loss after tax: ₹65.49 lakhs.
• Consolidated net loss after tax: ₹73.87 lakhs.
• Standalone EPS: ₹-0.75 per share.
• Dividend not declared for FY2025-26.

Operations & Capacity

• Ankleshwar and Bhatpore facilities strengthened; Surat production now full-fledged.
• Surat freeze-drying capacity added: 450 kg/day.
• 350 kVA solar power plant commissioned at Ankleshwar.
• Kosher certification obtained for Ankleshwar facility.
• Capacity utilization ~18 tons/month per plant (22 installed).

Capital & Dividends

• Bonus issue: 4,356,000 shares (1:1).
• Authorized capital increased to ₹10 crore.
• Paid-up capital ₹8.712 crore.

Governance & Board

• Radhika Kanodiya resigned as Independent Director on 23 Jun 2025.
• Shivali Rajpurohit appointed as Additional Director on 25 Aug 2025.
• Shivali Rajpurohit regularised as Independent Director on 24 Nov 2025.
• Pallavi Herrik Shah to be re-appointed as Director.
• Board met 10 times in FY2025-26; committees formed and reconstituted.

Strategy & Growth

• Strategic shift from manufacturing to consumer brands.
• Focus on FzyEzy and OxyNXT brands.
• Export expansion and international markets focus.

Risks & Outlook

• Risks include raw material price volatility and currency fluctuations.
• Tariffs/regulatory changes affecting exports pose risk.
• Seasonality of agricultural inputs may impact volumes.

Related Party Transactions

• Related party transactions disclosed; director remuneration and loans.
• Transactions with HSDL, V4U Healthcare, Adinath, Mahavir, and others.

AGM Details

• AGM on 9 September 2026 at 12:00 PM at the registered office; mode: in-person.

Key Decisions

• Approved Board Report for FY ended 31 March 2026.
• Approved the 19th AGM notice for FY2026 on Sept 9, 2026 at 12:00.
• Approved draft Annual Report for FY2026.
• Recommended ordinary resolution for re-appointment of Pallavi Herrik Shah.
• Shifting of registered office from Ankleshwar to Surat within Gujarat; subject to AGM approval.
• Appointed M/s Richa Goyal & Associates as Scrutinizer for AGM voting.
• Fixation of Cut-off Date for eligibility to vote on AGM resolutions.

Demat/remat status

• No dematerialisation/rematerialisation requests were received during the quarter ended 30 June 2026.
• Regulation not applicable as the entire holding is in demat form.

Key Managerial Personnel

• MD Herrik Mountbaton Shah designated Managing Director; contact details provided.
• Shrenikkumar Mountkumar Shah designated Whole-time Director.
• Mitali Shrenikkumar Shah designated Chief Financial Officer.
• Ravi Baheti designated Company Secretary and Compliance Officer.
• Contact details include email hamps.bio@gmail.com and phones 8000001113, 8000006663.
• Registered office Bharuch and corporate office Surat details.

Appointment Details

• Appointee: Ravi Baheti as Company Secretary and Compliance Officer.
• Effective date: 6 July 2026.
• Reason for change: appointment to fill the CS & CO vacancy.
• Profile: ICSI Associate, Membership No. A49472; B.Com (Hons); 9+ years' governance experience.
• Experience: 9+ years in secretarial, governance, and compliance management.
• Relationship with directors/promoters: none/not applicable.
• Governance role: board authorised KMPs to determine materiality for disclosures.

Target Entity

• HSDL Innovative Private Limited is the target entity acquired
• The target is incorporated in India (CIN: U15136GJ2017PTC095843)

Acquisition Details

• 100% equity shares of HSDL Innovative Private Limited acquired
• Acquisition completed on March 25, 2026
• HSDL Innovative Private Limited became a wholly owned subsidiary of Hamps Bio Limited

Consideration and Price

• Total purchase consideration was INR 2.04 crore paid in cash
• Shares purchased from existing shareholder